Belatacept denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for belatacept are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Belatacept as Non-Formulary

Belatacept's placement on UnitedHealthcare formularies varies by plan and contract year. A non-formulary denial means the drug is either excluded from your specific plan's drug list or sits on a tier that requires additional review before coverage is authorized. This is a coverage-structure issue, not a judgment that belatacept is medically inappropriate for transplant recipients — and it is one of the most successfully appealed denial types.

## Why This Denial Is Appealable

Federal and state rules require plans to cover non-formulary drugs when no formulary alternative is medically appropriate for a given patient. If your transplant physician can document that the covered alternatives are unsuitable — due to toxicity history, drug interaction profile, or clinical circumstances specific to you — the plan must consider an exception. This is called a formulary exception or medical-necessity exception request.

## Federal Appeal Framework

• ACA §2719 external review: Available after exhausting internal appeals. An IRO independently evaluates whether the non-formulary exclusion, as applied to your case, is consistent with accepted medical practice. File within approximately four months of your denial (confirm the exact deadline on your EOB).
• ERISA §503: Employer-plan members are entitled to the specific plan language and formulary-exception criteria used to deny coverage.
• Expedited track: Available when standard timelines would seriously jeopardize the patient's health — relevant for transplant patients at imminent rejection risk.

## Concrete Appeal Steps

1. Obtain a copy of your plan's formulary-exception policy and the belatacept-specific exclusion language. 2. Ask your transplant center to identify every formulary-listed immunosuppressant and document — with chart evidence — why each is not appropriate for your situation. 3. Request a formulary exception simultaneously with your internal appeal to save time. 4. If denied internally, escalate to external IRO review immediately.

## Documentation to Gather

• Transplant diagnosis and history: operative and pathology records establishing transplant status.
• Formulary-alternative trial and failure history: for each drug on the covered tier, chart notes showing dates of use, doses, and reason for discontinuation or why it was never trialed (with clinical rationale).
• Prescriber letter addressing formulary alternatives: your physician should state, referencing the FDA-approved prescribing label for belatacept and the applicable transplant guideline organization, why this specific medication is necessary and alternatives are inadequate.
• Current clinical status: recent labs and notes showing kidney function and immunologic stability to establish stakes.

## Criteria-Mapping Structure

Download UnitedHealthcare's published formulary-exception criteria for specialty immunosuppressants. Copy each criterion verbatim into a table. In the adjacent column, cite the exact document, date, and chart fact that satisfies it. Reviewers and IRO panelists respond well to this format because it eliminates ambiguity about whether your evidence maps to each required element.